Kairos Pharma announces interim Phase I data for ENV-105 in NSCLC

Kairos Pharma has reported interim safety results from its ongoing Phase I trial of ENV-105, along with AstraZeneca's Tagrisso, in advanced EGFR-mutated NSCLC. The trial reported that none of the 13 patients treated so far have experienced serious adverse events related to ENV-105. The combination therapy is being assessed in patients who have developed resistance to osimertinib, the global standard for EGFR-mutated NSCLC. Credit: Arif biswas / Shutterstock.com. Kairos Pharma has reported interim safety results from its ongoing Phase I clinical trial of ENV-105 (carotuximab), along with AstraZeneca’s Tagrisso (osimertinib), in patients with advanced epidermal growth factor receptor (EGFR)-mutated non-small…

Source: Clinical Trials Arena